Welcome to our dedicated page for Nasus Pharma news (Ticker: NSRX), a resource for investors and traders seeking the latest updates and insights on Nasus Pharma stock.
Nasus Pharma Ltd. (NSRX) is a clinical-stage pharmaceutical company whose news flow centers on the development of intranasal powder products for acute and emergency medical conditions. As a NYSE American–listed issuer and foreign private filer, the company regularly releases updates that are of interest to investors following emerging healthcare and drug delivery platforms.
News about Nasus Pharma frequently highlights progress in its lead program, NS002, an investigational intranasal epinephrine powder formulation being developed as a needle-free alternative to epinephrine autoinjectors for anaphylaxis. Coverage includes early clinical trial results, regulatory milestones such as Health Canada authorization for a Phase 2 study, and announcements related to dosing of participants and study design details.
Company press releases also address corporate and capital markets events. These include the pricing and closing of its initial public offering, the approval and commencement of trading of its ordinary shares on the NYSE American under the symbol NSRX, and ceremonial milestones such as ringing the closing bell at the New York Stock Exchange. Such items provide context on Nasus Pharma’s transition to the public markets and its stated use of proceeds to advance the intranasal epinephrine program and general corporate activities.
In addition, Nasus Pharma issues news on strategic collaborations and leadership changes. Announcements have described expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support development and planned commercialization of NS002 through device technology, development services, and supply arrangements. Leadership updates, such as the appointment of an Executive Vice President and Chief Financial Officer, are also disclosed, along with shareholder communications like the CEO’s letter outlining clinical, regulatory, and corporate priorities.
Investors and observers who follow NSRX news can use this page to review company press releases and related coverage that track Nasus Pharma’s clinical development, regulatory interactions, collaborations, governance developments, and capital markets activities over time.
Nasus Pharma (NYSE American: NSRX) announced that Chief Financial Officer Eyal Rubin will leave the company to pursue an opportunity outside the life science industry. Rubin will remain through September 18, 2026 to support a seamless and orderly transition.
Oren Elmaliach, currently Director of Finance, has been appointed Interim Chief Financial Officer. Elmaliach has been with Nasus since inception and is a certified public accountant with over 15 years of financial and life sciences experience, including work with US public markets and financial reporting. Nasus is a clinical-stage biopharmaceutical company developing intranasal therapies, led by product candidate NS002 for intranasal epinephrine in Type I allergic reactions, including anaphylaxis.
Nasus Pharma (NYSE:NSRX) reported unaudited financial results for the six months ended June 30, 2026 and provided a business update. Cash, cash equivalents and short‑term deposits rose to $11.9 million from $4.3 million at year‑end 2025, mainly due to a $15.0 million private placement, which the company expects will fund operations through the second quarter of 2027.
Nasus recorded a net loss of $5.9 million versus $1.3 million a year earlier, driven by higher R&D expenses of $2.6 million and G&A expenses of $3.4 million. Shareholders’ equity increased to $11.0 million, with 11.07 million weighted average ordinary shares outstanding.
Clinically, NS002, an intranasal epinephrine powder for anaphylaxis, completed a Phase 2 study showing statistically significant improvements in time to therapeutic threshold versus EpiPen and consistent absorption, and is planned to enter a pivotal trial in Q4 2026 with topline data expected in Q1 2027. NS003, an intranasal ondansetron powder for chemotherapy‑induced and post‑operative nausea and vomiting, showed positive preclinical pharmacokinetics and is on track for a first‑in‑human PK study in the coming weeks. Nasus also appointed pharma veteran Brendan P. O’Grady as CEO effective July 27, 2026.
Nasus Pharma (NYSE:NSRX) appointed pharmaceutical industry veteran Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026, succeeding Dan Teleman. According to Nasus Pharma, O'Grady will focus on unlocking the commercial potential of intranasal epinephrine candidate NS002, advancing the pipeline, business development and the Nasax intranasal technology platform.
The company plans to advance NS002 toward a pivotal trial in Q4 2026 with topline data expected in Q1 2027. O'Grady cites NS002’s opportunity in an estimated $2 billion anaphylaxis treatment market and its intranasal, rapid-onset profile versus injectable options. He brings over 35 years of global pharma leadership, including senior roles at Teva (CEO Teva USA, EVP North America Commercial), CEO of Assertio Holdings, board service at Amwell, and membership on the U.S. Investment Advisory Council.
Nasus Pharma (NYSE:NSRX) will present at the Zacks Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, held virtually on June 24-25, 2026.
The company’s live presentation is scheduled for June 24, 2026, from 11:00am to 11:30am Eastern Time, with real-time Q&A and a webcast replay available.
Nasus Pharma (NYSE:NSRX) reported positive preclinical pharmacokinetic and safety results for NS003, its intranasal powder ondansetron for chemotherapy and post-operative nausea and vomiting.
In animal studies, NS003 showed a PK profile comparable to intravenous ondansetron and a favorable safety profile, supporting a planned first-in-human PK study in Q3 2026.
Nasus Pharma (NYSE:NSRX) will host a virtual KOL event on June 10, 2026, at 8:00 AM ET.
The session will cover an overview of NS002, an epinephrine intranasal powder in development for anaphylaxis, review Phase 2 data versus EpiPen, and include a live Q&A.
Nasus Pharma (NYSE: NSRX) announced management will attend two investor conferences in New York in early May 2026. Chief Financial Officer Eyal Rubin will hold 1x1 investor meetings at the Market Movers Investor Summit on May 5, 2026 and the D. Boral Capital Global Conference on May 7, 2026. Interested investors should contact sponsoring institutions to request meetings.
Nasus Pharma (NYSE: NSRX) reported positive Phase 2 topline results for NS002, showing faster early epinephrine absorption versus EpiPen and consistent absorption under nasal allergic challenge. The company plans a pivotal study to start in Q4 2026 with a planned readout in Q1 2027, and believes results support a potential NDA filing.
Nasus is advancing NS003 and NS004 toward first-in-human studies in H2 2026 and is advancing NS005. As of Dec 31, 2025, cash and equivalents were $4.3 million; R&D was $2.4M, G&A $2.7M, and net loss $5.9M. Shares outstanding: 9,015,383.
Nasus Pharma (NYSE: NSRX) reported positive Phase 2 top line results for intranasal epinephrine NS002, showing faster and higher early absorption versus EpiPen®.
Key outcomes: median T100 1.69 vs 3.42 minutes (p=0.033), 88.4% vs 64.6% reached 100 pg/mL at 5 minutes (p=0.0081), ~50% higher AUC in the 10-minute window, comparable Cmax, no serious adverse events. Pivotal study planned for Q4 2026.
Nasus Pharma (NYSE: NSRX) will present topline analysis from the Phase 2 repeated dose clinical study of NS002, its intranasal powder epinephrine candidate, on March 16, 2026 at 8:00 a.m. ET. A question-and-answer session follows the data presentation.
Investors can join via live webcast (registration required) or dial-in, and a recording will be posted on the company investor relations website after the call.